Hyperliquid Strategies (PURR) investor relations material

Executive summary

• Achieved strong Q3 results with a $152.5M net profit, driven by significant appreciation in HYPE token price and disciplined treasury management, scaling HYPE holdings to 20M tokens.

• Completed exit from legacy Sonnet/bio-tech assets, retaining a 40% stake in Guidant BioTherapeutics, and transitioned to a pure-play digital asset treasury.

• Expanded ecosystem participation by launching a validator partnership with Unit/Trade XYZ, enhancing revenue and ecosystem alignment.

• Focused on capital-efficient HYPE exposure, alignment with Hyperliquid's deflationary mechanics, and bringing real world assets and outcome markets on-chain.

• Main business is accumulating and staking HYPE tokens to generate ongoing staking rewards.

Financial highlights

• Q3 net income reached $152.5M, reversing a prior quarter loss, mainly from $198.4M in unrealized HYPE gains; nine-month net loss was $165.4M due to earlier losses and a $35.6M IPR&D write-off.

• Treasury strategy income for the quarter was $202.4M, with $2.6M from staking and $1M from interest income.

• Cash and equivalents declined to $113.1M at quarter-end, while HYPE digital assets increased to $689M.

• Stockholders’ equity rose to $743.5M as of March 31, 2026, with no debt.

• Deferred tax expense for the quarter was $42.7M, with a liability of $60.5M recognized due to HYPE appreciation.

Outlook and guidance

• Expect continued growth from HIP-3 (real world assets), HIP-4 (outcome markets), portfolio margin, and validator revenue streams.

• Ongoing evaluation of cash deployment between operating needs and further HYPE purchases, with a minimum cash reserve target of $25M.

• Management expects existing resources to fund operations for at least 12 months and plans to seek additional funding as needed.

• Anticipate more institutional partners adopting Builder Codes and further ecosystem integration.